| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
101,390,000 |
| Market
Cap: |
1.63(B) |
| Last
Volume: |
668,805 |
Avg
Vol: |
666,964 |
| 52
Week Range: |
$12.32 - $16.78 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Innoviva is a company with a portfolio of royalties and other healthcare assets. Co.'s royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA®. Co. is entitled to royalty payments made by GSK under its agreements that assigned to Theravance Respiratory Company, LLC (TRC), including TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered or developed in the future under the Long-Acting Beta2 Agonist Collaboration Agreement and the Strategic Alliance Agreement with GSK, which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
215,000 |
664,000 |
| Total Buy Value |
$0 |
$0 |
$2,804,388 |
$8,468,005 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
5 |
12 |
| Total Shares Sold |
0 |
0 |
10,994 |
10,994 |
| Total Sell Value |
$0 |
$0 |
$153,810 |
$153,810 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
1 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
• – – |
2012-05-20 |
4 |
D |
$20.33 |
$77,905 |
D/D |
(3,832) |
342,220 |
|
- |
|
| Aguiar Michael W |
Sr VP, Chief Financial Officer |
• – – |
2012-05-20 |
4 |
D |
$20.33 |
$77,905 |
D/D |
(3,832) |
177,924 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2012-05-20 |
4 |
D |
$20.33 |
$77,905 |
D/D |
(3,832) |
237,285 |
|
- |
|
| Glaxosmithkline Plc |
10% Owner |
– – • |
2012-05-16 |
4 |
B |
$21.29 |
$212,887,000 |
I/I |
10,000,000 |
25,814,421 |
1.5 |
- |
|
| Levine Arnold J |
Director |
– • – |
2012-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
79,988 |
|
- |
|
| Malkiel Burton G |
Director |
– • – |
2012-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
30,000 |
|
- |
|
| Young William D |
Director |
– • – |
2012-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
46,129 |
|
- |
|
| Whitesides George M |
Director |
– • – |
2012-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
568,571 |
|
- |
|
| Waltrip William H |
Director |
– • – |
2012-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
62,258 |
|
- |
|
| Ringrose Peter S |
Director |
– • – |
2012-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
24,000 |
|
- |
|
| Gunderson Robert V Jr |
Director |
– • – |
2012-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
78,164 |
|
- |
|
| Fore Henrietta |
Director |
– • – |
2012-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
21,000 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2012-05-04 |
4 |
OE |
$3.10 |
$400,070 |
D/D |
63,225 |
532,527 |
|
- |
|
| Drazan Jeffrey M |
Director |
– • – |
2012-05-01 |
4 |
S |
$21.71 |
$186,402 |
D/D |
(8,586) |
33,465 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2012-02-20 |
4 |
D |
$18.54 |
$180,709 |
D/D |
(9,747) |
241,117 |
|
- |
|
| Aguiar Michael W |
Sr VP, Chief Financial Officer |
• – – |
2012-02-20 |
4 |
D |
$18.54 |
$185,734 |
D/D |
(10,018) |
181,756 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2012-02-20 |
4 |
D |
$18.54 |
$396,496 |
D/D |
(21,386) |
469,302 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2012-02-20 |
4 |
D |
$18.54 |
$98,596 |
D/D |
(5,318) |
86,343 |
|
- |
|
| Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
• – – |
2012-02-20 |
4 |
D |
$18.54 |
$178,373 |
D/D |
(9,621) |
346,052 |
|
- |
|
| Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
• – – |
2012-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
355,673 |
|
- |
|
| Aguiar Michael W |
Sr VP, Chief Financial Officer |
• – – |
2012-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
191,774 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2012-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
91,661 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2012-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
490,688 |
|
- |
|
| Blum Leonard M |
Sr VP, Chief Comm. Officer |
• – – |
2012-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
286,932 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2012-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
250,864 |
|
- |
|
704 Records found
|
|
Page 17 of 29 |
|
|
0.07 (0.43%) 
